2020
DOI: 10.1038/s41423-020-0426-7
|View full text |Cite
|
Sign up to set email alerts
|

Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

11
338
1
2

Year Published

2020
2020
2021
2021

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 345 publications
(352 citation statements)
references
References 19 publications
11
338
1
2
Order By: Relevance
“…We described a detailed protocol for producing SARS-CoV-2 Spike-pseudotyped lentiviral particles and performing neutralization assays. Although this basic pseudotyping approach has been described previously [4,12,27,29,[37][38][39][40][41], we provided the first detailed protocol that made all reagents available in a public repository (https://www.beiresources.org/). We hope this protocol and reagents will more easily enable others to assess the neutralizing activity of antibodies and sera reactive to SARS-CoV-2.…”
Section: Discussionmentioning
confidence: 99%
“…We described a detailed protocol for producing SARS-CoV-2 Spike-pseudotyped lentiviral particles and performing neutralization assays. Although this basic pseudotyping approach has been described previously [4,12,27,29,[37][38][39][40][41], we provided the first detailed protocol that made all reagents available in a public repository (https://www.beiresources.org/). We hope this protocol and reagents will more easily enable others to assess the neutralizing activity of antibodies and sera reactive to SARS-CoV-2.…”
Section: Discussionmentioning
confidence: 99%
“…For some of the recovered patients, protective antibodies have been described. They are mainly directed towards the receptor binding domain of the spike protein, and most likely, they interfere with viral entry [40]. Even if the majority of patients recover, some of them after discharge from the hospital, asymptomatic and negative RT-PCR viral RNA tests remain/return positive or even relapse [41].…”
Section: Sars-cov-2 Infection and The Pathophysiology Of Cytokine Relmentioning
confidence: 99%
“…NAbs from recovered COVID-19 patients (24,25). S protein fragments containing the RBD have yielded multiple RBD-targeting NAbs that can neutralize SARS-CoV-2 (24,25).…”
mentioning
confidence: 99%
“…NAbs from recovered COVID-19 patients (24,25). S protein fragments containing the RBD have yielded multiple RBD-targeting NAbs that can neutralize SARS-CoV-2 (24,25). In light of the rapid emergence of escape mutants in the RBD of SARS-CoV and MERS, monoclonal NAbs targeting other epitopes than the RBD are a welcome component of any therapeutic antibody cocktail (26,27).…”
mentioning
confidence: 99%